Top

Published in:

01-06-2013 | Colorectal Cancer

Combined Modality Therapy for Rectal Cancer: Too Much Too Often?

Author: Martin R. Weiser, MD

Published in: Annals of Surgical Oncology | Issue 6/2013

Excerpt

The refinement and implementation of multimodal therapy for rectal cancer, including surgery, radiotherapy, and chemotherapy, is certainly one of the most meaningful achievements in the history of clinical cancer research to date. It is thus important to set any harsh critique of current treatment methods and outcomes within this context. …

Farias EF, Ong DE, Ghyselinck NB, Nakajo S, Kuppumbatti YS, Mira y Lopez R. Cellular retinol-binding protein I, a regulator of breast epithelial retinoic acid receptor activity, cell differentiation, and tumorigenicity. J Natl Cancer Inst. 2005;97:21–9.PubMedCrossRef

Gastrointestinal Tumor Study Group. Prolongation of the disease-free interval in surgically treated rectal carcinoma. N Engl J Med. 1985;312:1465–72.CrossRef

Cohen AM, Minsky BD. Aggressive surgical management of locally advanced primary and recurrent rectal cancer. Current status and future directions. Dis Colon Rectum. 1990;33:432–8.PubMedCrossRef

Salo JC, Paty PB, Guillem J, Minsky BD, Harrison LB, Cohen AM. Surgical salvage of recurrent rectal carcinoma after curative resection: a 10-year experience. Ann Surg Oncol. 1999;6:171–7.PubMedCrossRef

Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926–33.PubMedCrossRef

Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Engl J Med. 1997;336:980–7.

Lange M, et al. Long term results of rectal cancer surgery with a systematical operative approach. Ann Surg Oncol. doi:10.1007/s10350-008-9328-y.

Loos M, et al. Effect of preoperative radio(chemo)therapy on long-term functional outcome in rectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol. doi: 10.1245/s10434-012-2827-z.

Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? Br J Surg. 1982;69:613–6.PubMedCrossRef

10.

Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet. 1986;1(8496):1479–82.PubMedCrossRef

11.

Enker WE, Thaler HT, Cranor ML, Polyak T. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg. 1995;181:335–46.PubMed

12.

Enker WE. Potency, cure, and local control in the operative treatment of rectal cancer. Arch Surg. 1992;127:1396–401.PubMedCrossRef

13.

Nagtegaal ID, van de Velde CJ, van der Worp E, Kapiteijn E, Quirke P, van Krieken JH; Cooperative Clinical Investigators of the Dutch Colorectal Cancer Group. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol. 2002;20:1729–34.PubMedCrossRef

14.

Lange MM, den Dulk M, Bossema ER, Cooperative Clinical Investigators of the Dutch Total Mesorectal Excision Trial, et al. Risk factors for faecal incontinence after rectal cancer treatment. Br J Surg. 2007;94:1278–84.PubMedCrossRef

15.

Peeters KC, van de Velde CJ, Leer JW, et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol. 2005;23:6199–206.PubMedCrossRef

16.

Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. Int J Radiat Oncol Biol Phys. 2002;54:386–96.PubMedCrossRef

17.

Gunderson LL, Callister M, Marschke R, Young-Fadok T, Heppell J, Efron J. Stratification of rectal cancer stage for selection of postoperative chemoradiotherapy: current status. Gastrointest Cancer Res. 2008;2:25–33.PubMed

18.

Gunderson LL, Sargent DJ, Tepper JE, et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol. 2004;22:1785–96.PubMedCrossRef

19.

Cercek A, Weiser MR, Goodman KA, et al. Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation. J Clin Oncol. 2010;28(15 Suppl):3649.

20.

Schrag D, Weiser MR, Goodman KA, et al. Neoadjuvant FOLFOX-bev, without radiation, for locally advanced rectal cancer. J Clin Oncol. 2010;28(15 Suppl):3511.

Title: Combined Modality Therapy for Rectal Cancer: Too Much Too Often?
Author: Martin R. Weiser, MD
Publication date: 01-06-2013
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 6/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-013-2939-0

At a glance: The STEP trials

Springer Medicine

Combined Modality Therapy for Rectal Cancer: Too Much Too Often?

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 6/2013

Impact of Lymph Node Ratio on Survival in Papillary Thyroid Cancer

Effect of Preoperative Radio(chemo)therapy on Long-term Functional Outcome in Rectal Cancer Patients: A Systematic Review and Meta-analysis

Disparities in Pancreas Cancer Care

Risk of Occult Irresectable Disease at Liver Resection for Hepatic Colorectal Cancer Metastases: A Contemporary Analysis

Factors Associated with Breast MRI Use: A Population-Based Analysis

Surgical Resection in Hepatocellular Carcinoma Patients with Minimal Background Fibrosis: A Strategy in the Era of Organ Shortage